Camurus AB
STO:CAMX

Watchlist Manager
Camurus AB Logo
Camurus AB
STO:CAMX
Watchlist
Price: 664.5 SEK 0.68% Market Closed
Market Cap: 39.1B SEK

Relative Value

The Relative Value of one CAMX stock under the Base Case scenario is 1 344.02 SEK. Compared to the current market price of 664.5 SEK, Camurus AB is Undervalued by 51%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CAMX Relative Value
Base Case
1 344.02 SEK
Undervaluation 51%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
38
vs Industry
8
Median 3Y
16.1
Median 5Y
17.4
Industry
2.4
Forward
13.2
vs History
25
vs Industry
4
Median 3Y
80.1
Median 5Y
37.8
Industry
20.3
Forward
40
vs History
17
vs Industry
4
Median 3Y
85.7
Median 5Y
30.3
Industry
15.6
vs History
12
vs Industry
4
Median 3Y
63.2
Median 5Y
-15.4
Industry
23.1
vs History
61
vs Industry
5
Median 3Y
12.2
Median 5Y
12.2
Industry
2
vs History
36
vs Industry
9
Median 3Y
15.5
Median 5Y
16.3
Industry
2.5
Forward
12.2
vs History
38
vs Industry
10
Median 3Y
16.9
Median 5Y
18.4
Industry
4.8
vs History
30
vs Industry
5
Median 3Y
68.6
Median 5Y
30.5
Industry
12.5
Forward
30.2
vs History
25
vs Industry
5
Median 3Y
65.9
Median 5Y
29
Industry
15.7
Forward
33.3
vs History
19
vs Industry
5
Median 3Y
78.5
Median 5Y
28.4
Industry
14.1
vs History
17
vs Industry
5
Median 3Y
84.9
Median 5Y
28.8
Industry
17.6
vs History
7
vs Industry
2
Median 3Y
28.8
Median 5Y
20
Industry
1.8

Multiples Across Competitors

CAMX Competitors Multiples
Camurus AB Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Camurus AB
STO:CAMX
39.1B SEK 20.9 91.3 73.8 76
US
Eli Lilly and Co
NYSE:LLY
734.6B USD 15 66.1 35.5 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371.6B USD 4.2 17 12.5 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.7 19.4 12.8 14.6
CH
Roche Holding AG
SIX:ROG
215.9B CHF 3.6 26.1 9.8 11.4
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP 4 28.5 131.6 198.5
CH
Novartis AG
SIX:NOVN
182.1B CHF 4.1 17.2 10.1 13.6
US
Merck & Co Inc
NYSE:MRK
199.8B USD 3.1 11.5 8.2 9.9
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
120.1B EUR 1.3 9.5 5.2 6.1
P/E Multiple
Earnings Growth PEG
SE
Camurus AB
STO:CAMX
Average P/E: 31.8
91.3
79%
1.2
US
Eli Lilly and Co
NYSE:LLY
66.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.4
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.1
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
28.5
36%
0.8
CH
Novartis AG
SIX:NOVN
17.2
17%
1
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.5
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Camurus AB
STO:CAMX
Average EV/EBITDA: 400.7
73.8
82%
0.9
US
Eli Lilly and Co
NYSE:LLY
35.5
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
UK
AstraZeneca PLC
LSE:AZN
131.6
9%
14.6
CH
Novartis AG
SIX:NOVN
10.1
5%
2
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.2
8%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Camurus AB
STO:CAMX
Average EV/EBIT: 1 703.9
76
79%
1
US
Eli Lilly and Co
NYSE:LLY
38.8
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
198.5
21%
9.5
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
US
Merck & Co Inc
NYSE:MRK
9.9
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.1
14%
0.4